Mankind Pharma's ESG Rating Improves to 'Strong' Category with 64 Score
Mankind Pharma's ESG rating improved to 64 ('Strong' category) from 57 ('Adequate'). Core ESG rating increased to 71 from 60. CRISIL ESG Ratings provided the independent assessment based on FY2026 disclosures and public information. The details are available on the company's website.
An improved ESG rating can enhance investor confidence and attract socially responsible investment, potentially impacting the company's long-term valuation and access to capital.
The company's ESG rating has improved significantly, moving from 'Adequate' to 'Strong' category, indicating positive progress in its environmental, social, and governance practices.
Mankind Pharma Limited has announced an improvement in its Environmental, Social, and Governance (ESG) rating. CRISIL ESG Ratings & Analytics Limited has assigned the company an ESG Rating of 64, placing it in the "Strong" category. This marks an increase from the previous rating of 57, which was in the "Adequate" category.
Furthermore, the company's Core ESG Rating has also seen an upward revision, moving from 60 to 71. It is important to note that Mankind Pharma did not engage CRISIL ESG Ratings for this assessment. The rating was independently prepared by CRISIL ESG Ratings based on disclosures for FY2026 and publicly available information.
The updated ESG disclosure is now available on the company's official website, www.mankindpharma.com.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.